2.42
price down icon9.70%   -0.26
after-market アフターアワーズ: 2.42
loading
前日終値:
$2.68
開ける:
$2.47
24時間の取引高:
10,589
Relative Volume:
0.69
時価総額:
$3.48M
収益:
-
当期純損益:
$-8.22M
株価収益率:
-0.325
EPS:
-7.4459
ネットキャッシュフロー:
$-4.78M
1週間 パフォーマンス:
-5.84%
1か月 パフォーマンス:
-10.37%
6か月 パフォーマンス:
-19.87%
1年 パフォーマンス:
-48.37%
1日の値動き範囲:
Value
$2.42
$2.534
1週間の範囲:
Value
$2.42
$2.78
52週間の値動き範囲:
Value
$2.15
$6.217

Synaptogenix Inc Stock (SNPX) Company Profile

Name
名前
Synaptogenix Inc
Name
セクター
Healthcare (1164)
Name
電話
(973) 242-0005
Name
住所
1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK
Name
職員
0
Name
Twitter
Name
次回の収益日
Name
最新のSEC提出書
Name
SNPX's Discussions on Twitter

SNPX を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
SNPX
Synaptogenix Inc
2.42 3.48M 0 -8.22M -4.78M -7.4459
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.82 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
634.23 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
591.87 36.10B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
270.02 35.03B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
272.17 28.24B 3.81B -644.79M -669.77M -6.24

Synaptogenix Inc (SNPX) 最新ニュース

pulisher
Mar 25, 2025

Will Synaptogenix Make A Mark In Synaptic Regeneration? - RTTNews

Mar 25, 2025
pulisher
Mar 20, 2025

Synaptogenix stock hits 52-week low at $2.15 amid market challenges - Investing.com Australia

Mar 20, 2025
pulisher
Mar 20, 2025

Synaptogenix stock hits 52-week low at $2.15 amid market challenges By Investing.com - Investing.com South Africa

Mar 20, 2025
pulisher
Mar 14, 2025

Ensysce Biosciences Stock Price, Quotes and Forecasts | NASDAQ:ENSC - Benzinga

Mar 14, 2025
pulisher
Mar 13, 2025

Synaptogenix (NASDAQ:SNPX) Trading Down 0.3% – Here’s Why - Defense World

Mar 13, 2025
pulisher
Mar 07, 2025

Sonnet BioTherapeutics Stock Price, Quotes and Forecasts - Benzinga

Mar 07, 2025
pulisher
Mar 06, 2025

Mustang Bio Stock Price, Quotes and Forecasts | NASDAQ:MBIO - Benzinga

Mar 06, 2025
pulisher
Mar 06, 2025

Aptevo Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:APVO - Benzinga

Mar 06, 2025
pulisher
Feb 07, 2025

ZyVersa Therapeutics (NASDAQ:ZVSA) Stock Quotes, Forecast and News Summary - Benzinga

Feb 07, 2025
pulisher
Jan 20, 2025

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.18% - MSN

Jan 20, 2025
pulisher
Jan 02, 2025

Finance Watch: As Cash Dwindles, Biotechs Cut Costs, Sell Assets, Merge, Assess Options - News & Insights

Jan 02, 2025
pulisher
Dec 24, 2024

Synaptogenix Forms Special Committee to Explore Value Creation Opportunities Utilizing Balance Sheet Strength - Marketscreener.com

Dec 24, 2024
pulisher
Dec 22, 2024

Synaptogenix (SNPX) Extends CEO’s Employment and Forms Special Committee to Explore Strategic Opportunities - Defense World

Dec 22, 2024
pulisher
Dec 21, 2024

Synaptogenix forms committee to explore strategic opportunities - Investing.com

Dec 21, 2024
pulisher
Dec 20, 2024

Synaptogenix forms committee to explore strategic opportunities By Investing.com - Investing.com South Africa

Dec 20, 2024
pulisher
Dec 20, 2024

Synaptogenix Restructures Leadership Amid Strategic Refocus - TipRanks

Dec 20, 2024
pulisher
Dec 20, 2024

Synaptogenix Forms Special Committee to Explore Strategic Options with $19.6M Cash Runway - StockTitan

Dec 20, 2024
pulisher
Dec 07, 2024

Synaptogenix shareholders approve key proposals at annual meeting - Investing.com India

Dec 07, 2024
pulisher
Dec 07, 2024

Synaptogenix shareholders approve key proposals at annual meeting By Investing.com - Investing.com Canada

Dec 07, 2024
pulisher
Nov 13, 2024

Synaptogenix stock hits 52-week low at $2.71 amid market challenges - Investing.com

Nov 13, 2024
pulisher
Nov 05, 2024

SNPX Stock Earnings: Synaptogenix Reported Results for Q1 2024 - MSN

Nov 05, 2024
pulisher
Oct 15, 2024

Comparing Synaptogenix (NASDAQ:SNPX) & Clever Leaves (NASDAQ:CLVR) - Defense World

Oct 15, 2024
pulisher
Oct 05, 2024

Synaptogenix appoints new auditor as Morison Cogen exits - Investing.com

Oct 05, 2024
pulisher
Oct 04, 2024

Synaptogenix appoints new auditor as Morison Cogen exits By Investing.com - Investing.com UK

Oct 04, 2024
pulisher
Sep 24, 2024

Synaptogenix, Inc. announced that it expects to receive $3.207 million in funding - Marketscreener.com

Sep 24, 2024
pulisher
Sep 13, 2024

Synaptogenix announces new preferred stock series - Investing.com

Sep 13, 2024
pulisher
Sep 11, 2024

Synaptogenix Announces $5.0 Million Financing - citybiz

Sep 11, 2024
pulisher
Sep 11, 2024

Synaptogenix secures $5 million in preferred stock financing - Investing.com India

Sep 11, 2024
pulisher
Jul 06, 2024

Polyrizon Stock Price, Quotes and Forecasts | NASDAQ:PLRZ - Benzinga

Jul 06, 2024
pulisher
Jul 03, 2024

Synaptogenix cleared to launch Phase 1 trial of bryostatin-1 in MS - Multiple Sclerosis News Today

Jul 03, 2024
pulisher
Jun 27, 2024

FDA grants IND authorisation for Synaptogenix’s multiple sclerosis trial - Clinical Trials Arena

Jun 27, 2024
pulisher
Apr 03, 2024

Synaptogenix announces reverse stock split to regain Nasdaq compliance By Investing.com - Investing.com South Africa

Apr 03, 2024
pulisher
Feb 22, 2024

Why NVIDIA Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket - Markets Insider

Feb 22, 2024
pulisher
Dec 19, 2023

Synaptogenix President Daniel L. Alkon, M.D. Honored for Scientific Presentation at USC-Sponsored Forum on Age-Related Diseases and Neurodegenerative Disorders - PR Newswire

Dec 19, 2023
pulisher
Nov 02, 2023

Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The TechnionIsrael Institute of Technology - PR Newswire

Nov 02, 2023
pulisher
Oct 16, 2023

'Extremely important outcome for Alzheimer's patients' following Synaptogenix trial - OutSourcing-Pharma.com

Oct 16, 2023
pulisher
Oct 06, 2023

Advanced Alzheimer's: Bryostatin-1 may be safe, effective - Medical News Today

Oct 06, 2023
pulisher
Sep 29, 2023

Bryostatin found to slow cognitive decline in advanced Alzheimer's... - Alzheimer's News Today

Sep 29, 2023
pulisher
Sep 19, 2023

Niemann-Pick Disease Type C Market to Proliferate by 2032, Predicts DelveInsight | Key Companies in the MarketAzafaros A.G., Cyclo Therapeutics, Inc., ZevraDenmark, Genzyme, IntraBio Inc, Mandos Health - PR Newswire

Sep 19, 2023
pulisher
Sep 13, 2023

Best Penny Stocks To Buy Now? 10 Under $1 To Watch - Penny Stocks

Sep 13, 2023
pulisher
Sep 07, 2023

Best Penny Stocks To Buy Now? 3 Under $1 To Watch - Penny Stocks

Sep 07, 2023
pulisher
Jul 20, 2023

Phase 1 trial of bryostatin-1 in MS expected by year's end |... - Multiple Sclerosis News Today

Jul 20, 2023
pulisher
Mar 28, 2023

Biodexa Pharmaceuticals (NASDAQ:BDRX) Stock Quotes, Forecast and News Summary - Benzinga

Mar 28, 2023
pulisher
Dec 19, 2022

Synaptogenix reports data from Phase II Alzheimer’s trial - Clinical Trials Arena

Dec 19, 2022
pulisher
Dec 16, 2022

Synaptogenix's Alzheimer's prospect flops in NIH-sponsored study, sinking stock - Fierce Biotech

Dec 16, 2022
pulisher
Oct 13, 2022

Theriva Biologics (AMEX:TOVX) Stock Quotes, Forecast and News Summary - Benzinga

Oct 13, 2022
pulisher
Sep 27, 2022

Roche's drug failure extends long list of Alzheimer's trial setbacks - Reuters.com

Sep 27, 2022
pulisher
Aug 15, 2022

PharmaCyte Biotech Reaches Cooperation Agreement with Iroquois Capital - Business Wire

Aug 15, 2022
pulisher
Jul 21, 2022

Synaptogenix Announces Corporate Update Conference Call - StockTitan

Jul 21, 2022
pulisher
Apr 14, 2022

Synaptogenix Inc (NASDAQ: SNPX) Announces a Peer-reviewed Paper on Bryostatin - BP Journal

Apr 14, 2022
pulisher
Nov 16, 2021

Synaptogenix: High-Risk High-Reward For Potential Alzheimer's Disease Treatment - Seeking Alpha

Nov 16, 2021

Synaptogenix Inc (SNPX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$70.69
price down icon 1.05%
$76.29
price down icon 2.18%
$31.13
price down icon 0.77%
$19.29
price down icon 5.07%
$91.06
price down icon 4.10%
biotechnology ONC
$272.17
price up icon 1.79%
大文字化:     |  ボリューム (24 時間):